Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: CMRF35-like molecule-1 (CLM-1) is a receptor of the CD300 family that inhibits MRGPRX2-mediated mast cell degranulation. Understanding the role and mechanism of CLM-1 agonist has significant implications for the treatment of allergic disease. Quercetin is a natural small molecule compound derived from plants and vegetables that has been shown to prevent histamine release by immune cells.
Objective: This study aims to examine the inhibitory effects of quercetin on MRGPRX2-mediated mast cell degranulation via CLM-1.
Results: We found that C48/80 stimulation resulted in significantly increased release of β-hexosaminidase, histamine and Ca in CLM-1-knockdown LAD2 cells than in NC-LAD2 cells. Surface plasmon resonance (SPR) and molecular docking analyses revealed high-affinity binding between quercetin and CLM-1 ( = 2.962×10 mol/L) mediated by the formation of hydrogen bonds. In addition, quercetin can selectively bind to CLM-1 on mast cells, leading to SHP-1 phosphorylation and subsequent inhibition of downstream MyD88/IKK/NF-κB signaling. Furthermore, activation of CLM-1 modulated the surface expression of MRGPRX2 by inhibiting F-actin, leading to internalization of the MRGPRX2 receptor via the PI3K/AKT/ Rac1/Cdc42 pathway.
Conclusion: Quercetin is a promising treatment for allergic diseases by acting as a CLM-1 agonist that inhibits MRGPRX2-mediated mast cell degranulation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468308 | PMC |
| http://dx.doi.org/10.2147/JIR.S480644 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Isoxanthohumol inhibits MRGPRX2-mediated mast cell activation reducing inflammation in rosacea.
Chin Med J (Engl)
September 2025
Department of Dermatology, Northwest Hospital, The Second Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China.
Chitin and chitosan, characterized by their extensive applications, abundant availability, and low cost, have been demonstrated to modulate immune responses. Mast cells (MCs) are important innate immune cells, and few studies on the regulation of MCs by chitin and chitosan were conducted. The key receptor Mas-related G protein-coupled receptor X2 (MRGPRX2), highly expressed in MCs, is involved in drug pseudo-allergic responses and several chronic diseases by mediating MC activation.
View Article and Find Full Text PDFSystemic administration of Neochamaejasmin B inhibits mast cell activation to reduce inflammation in a rosacea mouse model by targeting MRGPRX2.
Eur J Pharmacol
September 2025
Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Center for Dermatology Disease, Precision Medical Institute, Xi' an, China. Electronic address:
Rosacea is a chronic inflammatory disease characterised by facial erythema, telangiectasia, papules, pustules, and ocular manifestations. Mas-related G protein-coupled receptor X2 (MRGPRX2), suggested as a key receptor in the pathogenesis and inflammation of rosacea, is a potential therapeutic target to treat rosacea. Antibiotics are used to treat rosacea; however, drugs for targeted treatment are lacking.
View Article and Find Full Text PDFMRGPRX2-Mediated Mast Cell Degranulation by Monomethyl Methacrylate: Unveiling a Pathway in Bone Cement Implantation Syndrome.
Clin Exp Pharmacol Physiol
July 2025
Department of Pharmacology, Ehime University Graduate School of Medicine, Toon City, Japan.
Bone cement implantation syndrome is a critical complication of orthopaedic surgery, characterised by hypotension and hypoxemia. This syndrome is hypothesised to result from obstruction caused by fat droplets and the biochemical release of histamine caused by bone cement components. This study aimed to elucidate the histamine release mechanism, focusing on Mas-related G protein-coupled receptor X2 expressed on mast cells, which is hypothesised to be activated by bone cement components.
View Article and Find Full Text PDFSubnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models.
Signal Transduct Target Ther
April 2025
PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
The MAS-related G protein-coupled receptor-X2 (MRGPRX2), an orphan receptor expressed on mast cells (MCs), is upregulated upon inflammation and induces hypersensitivity and inflammatory diseases. In contrast to the large number of MRGPRX2 agonists, only a few antagonists have been described, and no optimization has been reported to improve potency, selectivity, and drug-like properties. Antagonists with ancillary inhibition of the putative mouse ortholog MRGPRB2 have not been described.
View Article and Find Full Text PDF